CASCADIAN THERAPEUTICS, INC. Financial Statements (2026 and earlier)
Company Profile
| Business Address |
3101 WESTERN AVE. SEATTLE, WA 98121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 101,998 | 122,729 | 125,889 | 62,805 | 71,638 | 80,879 | |||
| Cash and cash equivalent | 12,739 | 12,915 | 35,674 | 13,721 | 16,552 | 51,000 | |||
| Short-term investments | 89,259 | 109,814 | 90,215 | 49,084 | 55,086 | 29,879 | |||
| Other undisclosed current assets | 1,555 | 1,134 | 1,926 | 1,649 | 1,457 | 955 | |||
| Total current assets: | 103,553 | 123,863 | 127,815 | 64,454 | 73,095 | 81,834 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1,395 | 1,544 | 1,670 | 1,402 | 1,323 | 1,581 | |||
| Long-term investments and receivables | 10,981 | 2,686 | 10,244 | ||||||
| Long-term investments | 10,981 | 2,686 | 10,244 | ||||||
| Intangible assets, net (including goodwill) | 16,659 | 16,659 | 16,659 | 16,659 | 16,659 | 16,659 | |||
| Goodwill | 16,659 | 16,659 | 16,659 | 16,659 | 16,659 | 16,659 | |||
| Other noncurrent assets | 799 | 760 | 784 | 750 | 749 | 754 | |||
| Total noncurrent assets: | 29,834 | 21,649 | 29,357 | 18,811 | 18,731 | 18,994 | |||
| TOTAL ASSETS: | 133,387 | 145,512 | 157,172 | 83,265 | 91,826 | 100,828 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8,340 | 7,142 | 5,119 | 8,421 | 6,563 | 5,867 | |||
| Employee-related liabilities | 2,269 | 1,749 | 1,129 | 4,274 | 3,160 | 2,383 | |||
| Accounts payable | 619 | 297 | 1,028 | 824 | 741 | 1,310 | |||
| Accrued liabilities | 5,452 | 5,096 | 2,962 | 3,323 | 2,662 | 2,174 | |||
| Other undisclosed current liabilities | 393 | 392 | 262 | 352 | 803 | 393 | |||
| Total current liabilities: | 8,733 | 7,534 | 5,381 | 8,773 | 7,366 | 6,260 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 8 | 40 | 72 | 105 | 135 | 165 | |||
| Other liabilities | 8 | 40 | 72 | 105 | 135 | 165 | |||
| Total noncurrent liabilities: | 8 | 40 | 72 | 105 | 135 | 165 | |||
| Total liabilities: | 8,741 | 7,574 | 5,453 | 8,878 | 7,501 | 6,425 | |||
| Equity | |||||||||
| Equity, attributable to parent | 124,616 | 137,908 | 151,689 | 74,357 | 84,295 | 94,306 | |||
| Common stock | 353,852 | 353,852 | 353,852 | 353,849 | 353,860 | 353,860 | |||
| Additional paid in capital | 388,362 | 387,615 | 386,665 | 297,922 | 297,322 | 296,530 | |||
| Accumulated other comprehensive loss | (5,092) | (5,114) | (5,092) | (5,080) | (5,065) | (5,035) | |||
| Accumulated deficit | (612,506) | (598,445) | (583,736) | (572,334) | (561,822) | (551,049) | |||
| Total equity: | 124,616 | 137,908 | 151,689 | 74,357 | 84,295 | 94,306 | |||
| Other undisclosed liabilities and equity | 30 | 30 | 30 | 30 | 30 | 97 | |||
| TOTAL LIABILITIES AND EQUITY: | 133,387 | 145,512 | 157,172 | 83,265 | 91,826 | 100,828 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 50 | |||||||
| Operating expenses | (14,358) | (15,021) | (11,562) | (10,590) | (10,792) | (30,483) | ||
| Operating loss: | (14,358) | (15,021) | (11,562) | (10,590) | (10,792) | (30,483) | ||
| Nonoperating income (Other Nonoperating income) | 297 | 312 | 160 | 78 | 19 | 42 | ||
| Loss from continuing operations before income taxes: | (14,061) | (14,709) | (11,402) | (10,512) | (10,773) | (30,441) | ||
| Income tax benefit | 6,908 | |||||||
| Loss from continuing operations: | (14,061) | (14,709) | (11,402) | (10,512) | (10,773) | (23,533) | ||
| Loss before gain (loss) on sale of properties: | (14,061) | (14,709) | (11,402) | (10,512) | (10,773) | (23,533) | ||
| Net loss attributable to parent: | (14,061) | (14,709) | (11,402) | (10,512) | (10,773) | (23,533) | ||
| Other undisclosed net loss available to common stockholders, basic | (982) | (989) | (1,599) | |||||
| Net loss available to common stockholders, diluted: | (14,061) | (14,709) | (12,384) | (10,512) | (11,762) | (25,132) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | 9/30/2016 Q3 | 6/30/2016 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (14,061) | (14,709) | (11,402) | (10,512) | (10,773) | (23,533) | ||
| Other comprehensive income (loss) | 23 | (22) | (12) | (15) | (30) | 18 | ||
| Comprehensive loss: | (14,038) | (14,731) | (11,414) | (10,527) | (10,803) | (23,515) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (1) | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (14,038) | (14,732) | (11,414) | (10,527) | (10,803) | (23,515) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.